These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26707699)

  • 1. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.
    Kahn R; Berthold E; Gullstrand B; Schmidt T; Kahn F; Geborek P; Saxne T; Bengtsson AA; Månsson B
    Acta Paediatr; 2016 Apr; 105(4):427-32. PubMed ID: 26707699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs.
    Morozova N; Avramovič MZ; Markelj G; Toplak N; Avčin T
    Clin Rheumatol; 2024 Jul; 43(7):2287-2293. PubMed ID: 38775868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis.
    Berthold E; Månsson B; Gullstrand B; Geborek P; Saxne T; Bengtsson AA; Kahn R
    Scand J Rheumatol; 2018 Jan; 47(1):22-26. PubMed ID: 28485187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
    Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
    Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis.
    Cecamore C; Marsili M; Salvatore R; Troiani R; D'Egidio M; Tinari N; Pelliccia P; Chiarelli F; Marcovecchio ML; Breda L
    Mod Rheumatol; 2018 Jul; 28(4):637-641. PubMed ID: 29157059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
    Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
    Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
    De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
    J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D; Horneff G
    Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
    Su Y; Yang YH; Chiang BL
    Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
    Lahdenne P; Vähäsalo P; Honkanen V
    Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
    Gudbrandsdottir S; Larsen R; Sørensen LK; Nielsen S; Hansen MB; Svenson M; Bendtzen K; Müller K
    Clin Exp Rheumatol; 2004; 22(1):118-24. PubMed ID: 15005015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients.
    Spîrchez M; Samaşca G; Iancu M; Bolba C; Miu N
    Clin Lab; 2012; 58(3-4):253-60. PubMed ID: 22582498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
    Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
    Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis.
    Bašić J; Vojinović J; Jevtović-Stoimenov T; Despotović M; Sušić G; Lazarević D; Milošević V; Cvetković M; Pavlović D
    Clin Rheumatol; 2019 Jan; 38(1):117-124. PubMed ID: 30128913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
    Yeh KW; Lee CM; Chang CJ; Lin YJ; Huang JL
    PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.